Published Date: 17 Mar 2023
NEW DELHI: The National Medical Commission (NMC) has requested all medical schools to schedule examination appointments for Broad...
Read Full NewsA phase 2a trial showed that NLX-112 was safe and well tolerated in patients with Parkinson disease, while also reducing levodopa-induced dyskinesia and motor symptoms, supporting further clinical development.
AskBio noted that AB-1009 also recently received fast track and orphan drug designations from the FDA.
Amlitelimab Effective, Safe for Atopic Dermatitis in Patients 12 Years and Older
1.
Top Cancer Centers; Phase III Win in Prostate Cancer; Screening Recs for Anal Cancer
2.
AMA President-Elect Confronts a New Challenge: A Brain Tumor
3.
Radiotherapy after mastectomy can be avoided, study finds
4.
For patients with clear cell renal cell carcinoma, a new PET agent allows for same-day imaging.
5.
Base Treatment Decisions in Metastatic Breast Cancer on Presence of ESR1 Mutations
1.
Cowden Syndrome and Cancer: Understanding the Risk Factors
2.
Phosphate Vs. Phosphorus: What Is The Difference?
3.
Demystifying Lymphocytes: Everything You Need to Know
4.
Refractory Iron Deficiency Anemia in a Young Adult: Diagnostic Challenges
5.
Gut microbiota in curing cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
2.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
5.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation